article thumbnail

Injectable drug delivery market to value $1139.4b by 2029

European Pharmaceutical Review

A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable drugs are adopted widely as treatments for chronic infections such as HIV/AIDS and tuberculosis (TB).

article thumbnail

US legislation to benefit small molecule drug innovation

European Pharmaceutical Review

Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck obtains favourable US court ruling on sitagliptin patent lawsuit

Pharmaceutical Technology

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. Viatris is seeking approval from the US Food and Drug Administration (FDA) to market Januvia and Janumet’s generic versions in the country.

article thumbnail

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in 2029. According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98

article thumbnail

Scorpion inks deal with Pierre Fabre for next-gen EGFR inhibitors

Pharmaceutical Technology

The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. billion in 2029. GlobalData is the parent company of Pharmaceutical Technology.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. However, current orthopedic medical device trends all point towards the increasing use of such systems.

Medical 98
article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. However, current orthopedic medical device trends all point towards the increasing use of such systems.

Medical 52